Navigation Links
Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
Date:9/1/2008

6]** 1.8 [0.4-5.1]

60mg 15.2 [10.0-21.8]** 2.2 [0.6-5.4]

90mg 10.6 [6.2-16.6]** 2.3 [0.6-5.7]

#95% confidence interval, * p=0.005, **p<0.001, ***Major+Clinically

Relevant

About DU-176b

DU-176b is an oral anticoagulant that directly inhibits Factor Xa, a clotting factor in the blood. Daiichi Sankyo is developing DU-176b as a potential new treatment for the prevention of both arterial and venous thromboembolism.

About Daiichi Sankyo

A global pharmaceutical innovator, Daiichi Sankyo Co., Ltd., headed by President Takashi Shoda was established in 2005 through the merger of two leading Japanese pharmaceutical companies, Daiichi Pharmaceutical Co., Ltd. and Sankyo Co., Ltd. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. A central focus of Daiichi Sankyo's research and development is cardiometabolic diseases, including therapies for thrombosis, dyslipidemia, hypertension, diabetes, and acute coronary syndromes. Equally important to the company is the discovery of new medicines in the areas of infectious diseases, cancer, bone and joint diseases, and immune disorders. For more information, visit http://www.daiichisankyo.com.


'/>"/>
SOURCE Daiichi Sankyo
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
2. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
3. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
4. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... , March 31, 2015  InMed Pharmaceuticals ... stage biopharmaceutical company that specializes in developing safer, ... of Paul C. Anderson , Ph.D., to ... pharma industry veteran who brings significant drug discovery ... Anderson is a synthetic organic chemist by training ...
(Date:3/31/2015)... -- ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP ) ... and 300mg oral tablets, indicated for use in the ... Propafenone Hydrochloride 150mg, 225mg and 300mg tablets was $14 ... Arthur S. Przybyl , President and Chief Executive Officer ... our fourth product from the portfolio of approved generic ...
(Date:3/31/2015)... March 31, 2015  Oxis International, Inc. (OXIS) (OXI.PA) ... and commercialization, announced today Oxis CEO Tony Cataldo ... Oxis common shares on the Euronext exchange. Oxis shares ... symbol OXIS.   Oxis Chairman and CEO ... move forward with its strategies launched in 2014 and ...
Breaking Medicine Technology:InMed Pharmaceuticals Strengthens Scientific Advisory Board 2InMed Pharmaceuticals Strengthens Scientific Advisory Board 3InMed Pharmaceuticals Strengthens Scientific Advisory Board 4ANI Pharmaceuticals Announces the Launch of Propafenone Tablets 2ANI Pharmaceuticals Announces the Launch of Propafenone Tablets 3Oxis International Inc. Announces Request for Euronext Trading Suspension 2
... Oct. 7 Cleveland Clinic,s Top 10 Medical Innovations for ... therapies that are being developed to treat everything from deafness ... The list of breakthrough devices and therapies was selected by ... was unveiled during Cleveland Clinic,s 2009 Medical Innovation ...
... Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX ) today ... offering of 3.97 million shares of its common stock to ... gross proceeds of $3.97 million. , The shares were ... with the Securities and Exchange Commission that was declared effective ...
Cached Medicine Technology:Cleveland Clinic Unveils 'Top 10' Medical Innovations for 2010 2Cleveland Clinic Unveils 'Top 10' Medical Innovations for 2010 3Cleveland Clinic Unveils 'Top 10' Medical Innovations for 2010 4Catalyst Pharmaceutical Partners, Inc. Announces the Closing of $3.97 Million Registered Direct Offering 2
(Date:3/31/2015)... Dr. Parsa Mohebi, founder of Parsa Mohebi Hair ... the forefront of using beard hair to fill in ... a novelty has now become an absolute option for giving patients ... really do believe that beard to scalp hair transplant can be ... area isn’t as dense as we would like it,” says Dr. ...
(Date:3/31/2015)... CT (PRWEB) March 31, 2015 Calling all ... against Lyme and other tick-borne diseases! The first annual “Lyme ... Cove Island Park in Stamford, CT. The event, hosted by ... (TBDA), will raise funds to support research and education ... event, open to all ages and abilities, will feature 5K ...
(Date:3/31/2015)... 2015 OnChip Devices , a world ... silicon ESD diode chip targeted towards low voltage LED applications. ... Zeners are ideal for protecting circuits by suppressing voltage higher ... handle pulses of up to 350W and 20A, providing protection ... 61000-4-2 standard. These diodes do not exhibit any device ...
(Date:3/31/2015)... Scotch Plains, NJ (PRWEB) March 31, 2015 ... a board certified dermatologist by the American Board ... surgeon. After extensive dermatology research training at the ... Health, Dr. Li completed his internship in internal ... at the University of Pennsylvania in Philadelphia. Dr. ...
(Date:3/31/2015)... Dr. Uzma Parvez is having a busy ... conducted Grand Grounds Presentations at St. Michael’s Medical Center for ... Effects”. The event was attended by a large gathering ... positive feedback from the Grand Rounds. It was said ... in a while. , Ahead, Dr. Parvez has been ...
Breaking Medicine News(10 mins):Health News:Is Beard to Scalp Hair Transplant the Future? 2Health News:Lyme Research Alliance & Tick-Borne Disease Alliance to Kick-Off 1st “Lyme Walk & Run” Event, April 26 2Health News:OnChip Introduces Low Voltage Diodes for High-Brightness LED Protection 2Health News:Dr. Andrew Li of Warren Skin Care Center Is Celebrating 3 Years Recognized as an "NJ Top Doc" 2Health News:NJ Top Docs Presents, Dr. Uzma Parvez of Total Pain Care 2
... and none other than ‘gen–present’ and ‘gen-next’ can perfectly relate ... waters continue unabated, people are caught in a frenetic pace, ... seeking newer excitement propelled by desires of a ‘picture-postcard’ life ... is unacceptable - a mute submission to the vagaries of ...
... top Australian researchers have predicted what they hope to be ... transform the way patients are treated, within a period of ... have little choice but to take preventive action when faced ... John Shine, the executive director of the Garvan Institute of ...
... and Locker, Inc. conducted a voluntary recall of over 5,000 ... to alert consumers //of probable beef contamination that was processed ... President Jim Goeser said, "We should note that we have ... certified lab but the voluntary recall must proceed." ,It ...
... Pittsburgh by a team of scientists to study the people aged ... of their long life and to develop tactics to conquer the ... people. ,"The longer we wait, the more they're going ... Coles, the foundation's treasurer and a researcher who has studied the ...
... first death caused by dengue fever in Andhra Pradesh. ... of the state. ,Venkateswara Rao, director (medical ... Puttaparthi in Anantapur district. Two cases in Hyderabad, one ... dengue cases. ,Unofficial reports from different parts ...
... mental fog and forgetfulness and can no longer explain it ... new UCLA study shows that chemotherapy causes changes to the ... 10 years after treatment. Reported Oct. 5 in the online ... findings may help to explain the disrupted thought processes and ...
Cached Medicine News:Health News:Mental Health: Mind at Peace or in Pieces? 2Health News:Mental Health: Mind at Peace or in Pieces? 3Health News:Mental Health: Mind at Peace or in Pieces? 4Health News:Genetics to bring about Medical Breakthroughs 2Health News:Precautionary Recall of Beef over E.coli Contamination Concerns 2Health News:Supercentenarian Center to study longevity 2Health News:First confirmed Dengue death in Andhra Pradesh 2Health News:Chemotherapy's Effects on the Brain 2Health News:Chemotherapy's Effects on the Brain 3
Instrument set for carpal tunnel release....
Standard arthroscopy graspers for small joints. Also available are Mosquito Tip Graspers, 45 degree Forceps, SquareTrimmer Blunt Tip Forceps and SST Scoop Tip Forceps....
... SR™ Hand Implant System utilizes the same ... joint replacements. The SR™ Hand Implant ... other prostheses including minimal bone resection, surface ... articular surfaces, retention and/or repositioning of the ...
The efficient choice for small joint replacement technology -- the Ascension Silicone MCP features a similar design to our PyroCarbon MCP and utilizes the same instrumentation for intra-operative fle...
Medicine Products: